Clinical severity scores facilitate comparisons to understand risk factors for severe illness. For the 2022 multinational monkeypox clade IIb virus outbreak, we developed a 7-item Mpox Severity Scoring System (MPOX-SSS) with initial variables refined by data availability and parameter correlation. Application of MPOX-SSS to the first 200 patients diagnosed with mpox revealed higher scores in those treated with tecovirimat, presenting >3 days after symptom onset, and with CD4 counts <200 cells/mm3. For individuals evaluated repeatedly, serial scores were concordant with clinical observations. The pilot MPOX-SSS demonstrated good discrimination, distinguished change over time, and identified higher scores in expected groups.
CITATION STYLE
Zucker, J., McLean, J., Huang, S., DeLaurentis, C., Gunaratne, S., Stoeckle, K., … Brooks, J. T. (2024). Development and Pilot of an Mpox Severity Scoring System. Journal of Infectious Diseases, 229, S229–S233. https://doi.org/10.1093/infdis/jiad492
Mendeley helps you to discover research relevant for your work.